Submission of Outcome of board meeting and Financial Results for the quarter and year ended on 31st March 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Skybiotech Healthcare (formerly Kapil Cotex), a BSE smallcap with code 512036, reported FY2026 consolidated total income of Rs 740.38L, nearly flat vs Rs 743.45L in FY2025, indicating revenue stagnation. However, the company significantly narrowed its losses: consolidated PAT improved to Rs -111.68L from Rs -236.89L (a ~53% reduction in losses), and PBT loss narrowed from Rs -242.55L to Rs -166.66L. The standalone entity returned to profit with PAT of Rs 5.96L vs a loss of Rs -6.03L in the prior year. The auditors issued an unmodified (clean) opinion for both standalone and consolidated results, with no going concern or emphasis of matter qualifications. The subsidiary Skybiotech Life Sciences contributed a loss of Rs 105.72L to consolidated results.
The sharp narrowing of losses on flat revenue suggests cost optimisation but revenue growth remains a concern. The significant negative operating cash flow of Rs 151.58L on consolidated basis and declining cash balance to negative Rs 59.44L raises liquidity risk for a company already in loss-making territory. Investors should monitor cash position carefully despite the clean audit.